🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pleased to work with Lixte on interesting new anti cancer drug. last10k.com/sec-filings/li…

Very pleased to collaborate with Heparegenix to find oncology applications for their MKK4 inhibitor heparegenix.com/heparegenix-in…

The new lab neon sign. Kindly donated by Dr. Neto

We have identified factors that modulate the response to an interesting experimental cancer drug named indisulam. pubmed.ncbi.nlm.nih.gov/35534224/

Very proud to have been elected a member of the US National Academy of Science

Excited to share our first findings using the Lixte PP2A inhibitor LB-100. A very exciting drug with unique mechanism of action. pubmed.ncbi.nlm.nih.gov/35534224/

Pleased to join the board of directors of Lixte. LB-100 is a unique molecule that may help many cancer patients. I look forward to working with Lixte to bring this drug to the clinic by finding the right combinations and the right patient populations. stocktitan.net/news/LIXT/lixt…

Today we posted on BioRXiv an exciting new approach to cancer therapy, in which drug resistance is associated with loss of tumor forming capacity! biorxiv.org/cgi/content/sh…

Please check out our new publication in molecular oncology Molecular Oncology

Thank you Mark Foundation for funding our research on vulnerabilities of senescent cancer cells. lnkd.in/esEWm-yR

Kicking KRAS at AACR annual meeting Orlando

It’s combinations stupid! cell.com/cell/fulltext/…

We discovered a major role for PP2A in controlling splicing, suggesting that PP2A inhibition sensitizes to checkpoint immunotherapy by generating neo antigens. biorxiv.org/content/10.110…

When René Bernards Bernards Laboratory@NKI says he’s excited about new data, it’s time to pay attention 🔥👀 Be among the first to see these exciting data on ‘Unexpected, but Highly Synergistic Drug Combinations for Cancer Therapy’ at #EAISciencetoClinic: ow.ly/R86h50QAvzw

CRUK.org/open-letter

Because age-old problems may require truly innovative interventions... We're thrilled to announce that we've taken the first steps toward developing cancer therapy approaches that differ fundamentally from those pursued so far. #ParadoxicalIntervention

Very honored by the recognition by my British colleagues. royalsociety.org/news/2024/05/n…

Excited to be at EACR 2024 in Rotterdam